BHRF1, one of many Epstein-Barr virus (EBVI-encoded proteins, shows strong functional homology to the human bcl-2 proto-oncogene product, a protein involved in the pathogenesis of a subset of B-cell lymphomas, ie, follicle center cell lymphomas (FCCL). We have investigated the presence of possible latent and lytic transcripts of BHRFl using a rev e w transcriptase-polymerase chain reaction (RT-PCR)-based assay in a group of EBV-associated B-cell lymphomas in patients with (N = 5) or without overt immunodeficiency (N = 4). in T-cell lymphomas (N = 9). and in cases of Hodgkin's disease (N = 6). BHRFl transcription was found consistently in EBV-associated (ie, diffuse EBER 1/2-positive) B-cell lymphomas in patients with or without immune deficiency, whereas in EBV-associated T-cell lymphomas or in EBV-associated Hodgkin's disease, BHRFl transcription was only detected in two T-cell lymphomas and one case of Hodgkin's disease, which also harbored EBER 1/2-positive reactive cells. Moreover, weak BHRFl signals were found in two Tcell lymphomas where EBER 1/2 expression was detected mainly in sporadic reactive lymphocytes and in one reactive
PSTEIN-BARR virus (EBV) is the etiologic agent in
mononucleosis infectiosa' and has been implicated in the pathogenesis of certain malignancies. The virus can be detected in most, if not all, undifferentiated nasopharyngeal carcinomas (WC): and, depending on histologic type, in 10% to 70% of cases of Hodgkin's disease (HD).3 Moreover, EBV is detected in T-cell non-Hodgkin's lymphomas (T-NHL) depending on site, ranging from 5% in nodal T-cell lymphomas up to 100% in nasal T-cell lymphomas?-6 In Bcell lymphomas, EBV is classically associated with African Burkitt's lymphoma7 and with most lymphoproliferative disorders in immunocompromised
In other B-cell lymphomas in patients without overt immune deficiency, EBV is only detected in approximately 5% of cases." This is remarkable, because the majority of healthy individuals are latently infected by the virus, and B lymphocytes are probably the host cells for this latent EBV infection.".'' In biopsy material, EBV was shown to be present in morphologically malignant cells by either DNA in situ hybridization or by a more sensitive RNA in situ hybridization assay (RISH) using the abundantly transcribed noncoding EBER 112 RNAs.I3 Lymphomas with EBER 1/2-positive staining in the large majority of neoplastic cells were called EBVassociated lymphomas! In trying to identify the role of EBV in the pathogenesis of the different types of malignancies, the expression of specific EBV genes has been studied. Three different patterns of EBV latent gene expression emerged: latency types I, 11, and III.14 In Burkitt's lymphoma, expression is restricted to the EBER 1/2 genes, EBNAl and BARFOI5.I6 (latency type I). Latency type II (EBER 1/2, EBNA1, LMP1, BARFO, and often LMP2A andor LMP2B) was detected in NPC, HD, and T-cell 1ymphomas.'"'' In large B-cell lymphomas in immunocompromised patients, transcripts of all known EBV latent genes were detected (EBER 1/2; EBNAI, 2, 3A, B, and C; LMPI; LMP2A; LMP2B; and BARFO; latency tonsil with sporadic EBER 1/2-positive lymphocytes. BHRFl transcripts were found to be generated by the C or W promoter (associated with viral latency) and/or by the H promoter (associated with the virus lytic cycle). In all cases with H promoter-derived BHRFl transcripts, transcripts encoding ZEBRA were also detected, suggesting a reactivation of the virus lytic cycle. Analysis of other EBV genes revealed transcription of BARFO in all tested EBV-harboring tissues. Transcription of EBNAl and LMPl was usually detected, whereas EBNA2 transcription was found exclusively in B-cell lymphomas in immunocompromised patients. These data demonstrate that BHRFl transcripts are exclusively found in EBVassociated B-cell lymphomas. When BHRFI transcripts are detected in T-cell lymphomas or in Hodgkin's disease, it is probably due to the presence of reactive EBER 1/2-positive lymphocytes. The consistent transcription of BHRFl in EBVassociated B-cell lymphomas suggests a possible pathogenic role for this gene product in EBV-positive B-cell lymphomas analogous to bcl-2. type III).8.20*2' Thus, in different types of malignancies, different EBV genes are expressed.
Interestingly, one of the EBV genes, the BHRFl gene, shows partial sequence homology to the human bcl-2 protooncogene," a gene involved in the pathogenesis of a subset of B-cell lymphomas, ie, follicle center cell lymphomas (FCCL). Both BHRFl and bcl-2 are members of a growing family of proteins involved in regulation of apoptosis. All members share two highly conserved domains that are essential to their function.23324 Indeed, it has been shown that BHRFl can protect B lymphocytes from apoptosis in a similar way as the bcl-2 protein." Until recently, BHRFl has received relatively little attention in lymphoma research, mainly because BHRFl was primarely identified as a member of the early antigen complex,26 and it was shown that BHRFl is dispensable for transformation in ~itro.'~,'~ The regulation of BHRFl expression appears to be complex. High levels of mRNA and the 17-kD protein are detected early after activation of the lytic cycle.26 However, on Northem blot analysis, differentially spliced BHRFI-containing mRNAs were detected in tightly latent EBV-transformed lymphoblastoid cell lines, although at much lower levels.29 These BHRFl -containing mRNAs included the common leader sequences, characteristic of the EBNA family.29 Thus, BHRFl could also be expressed during latency.
To determine whether BHRFl is expressed in special types of lymphomas, we investigated the presence of possible latent (Y2/HF-spliced) and lytic (HUHF-spliced) transcripts of BHRFl using a reverse transcriptase-polymerase chain reaction (RT-PCR)-based assay in a group of EBVassociated B-cell lymphomas in patients with (N = 5 ) or without overt immune deficiency (N = 4), T-cell lymphomas (N = 9), and cases of HD (N = 6), as shown by the presence of EBER 1/2 RNAs in the majority of the malignant cells.
To further substantiate these data, we examined the presence of BHRFl transcripts in two T-cell lymphomas, where EBER 1/2 transcription was mainly found in nonneoplastic, reactive lymphocytes and in one hyperplastic tonsil harboring sporadic EBER 1/2-positive lymphocytes. The results indicate that BHRFl is transcribed exclusively in the neoplastic cells of EBV-associated B-cell lymphomas and in reactive lymphocytes, but not in the neoplastic cells of Tcell lymphomas or HD.
MATERIALS AND METHODS
Non-Hodgkin's lymphomas were classified according to the updated Kiel classification.30 EBV positivity was primarily shown by DNA PCR, using primers located on the BamHI W fragn~ent.~' EBVharboring cells were identified with a RISH assay using the EBER 1/2 probe as described previou~ly.~' For T-and B-cell lymphomas, the number of EBER 1/2-positive cells was visually estimated ac- 
EBV-Associated B-Cell Lymphomas in Immunocomprornised Patients
All five lymphomas consisted of diffuse polymorphous populations of large centroblastic cells with a variable number of CD30-positive blastoid cells, sometimes resembling Reed-Stemberg cells. Within 2 to 12 months, these lymphomas developed in patients who received an allogeneic bone marrow transplantation after having been treated for different malignancies.
EBV-Associated B-Cell Lymphomas in Patients Without Overt Immunodeficiency
The B-cell lymphomas included two polymorphous centroblastic lymphomas (tonsil, spleen), one diffuse centroblastic lymphoma (cervical lymph node), and one diffuse centroblastickentrocytic lymphoma (large, peritoneal tumor). These lymphomas showed a diffuse pattern of EBER 1/2-positive neoplastic cells (Fig lA) , comparable with the EBER 1/2 staining pattern observed in the B-cell lymphomas in immunocompromised patients. In the first three cases, a small but significant number (5% to 35%) of the neoplastic cells showed CD30 expression. In the last case, immunohistochemical staining on frozen sections for CD30 and LMPl was not possible due to poor quality of the material.
EBV-Associated T-cell Lymphomas
Six of the nine T-cell lymphomas have been described in detail elsewhere.' Three additional cases were obtained from the Department of Pathology, State University of Utrecht, Utrecht, The Netherlands. Sites of origin were nose (all pleiomorphic medium and largecell lymphoma, N = 7), lymph node (unclassifiable, N = l), and gut (large-cell anaplastic lymphoma, CD30-positive, N = 1). In the nasal T-cell lymphomas, the number of reactive lymphocytes as estimated by morphology was low, whereas in the latter two cases, the number of reactive lymphocytes was relatively high. EBER 1/2 expression in these cases was not restricted to the malignant cells but was also detected in a number of sporadic, small reactive lymphocytes (15 to 30 EBER 1/2-positive cells per section; Fig IC and Table 3 , cases 1660 and 1624).
EBV-Associated Cases of HD
Cases were classified as nodular sclerosing (N = 3) or as mixed cellularity (N = 2). In one case, the subtype could not be classified because the lymph node was only partially involved. In case 909, many infiltrating B lymphocytes were present. In all cases, the ReedSternberg and Hodgkin's cells were positive using the EBER 1/2 RISH assay, as well as by immunohistochemical staining for LMPl. However, in case 909, sporadic, small EBER l/Z-positive, but LMP1-negative, lymphocytes were also present (10 to 20 EBER l / 2-positive cells per section).
T-cell Lymphomas With EBER ID Positivity Mainly Restricted to Nonmalignant Cells
In previous studies, we and others have detected several lymphomas in which EBER 1/2-positive staining was mainly restricted to sporadic nonmalignant lymphocyte^.^.^^ We studied two nodal T-cell 
Hyperplastic Tonsil With Sporadic EBER ID-Positive L.ymphocyte.7
We studied 14 hyperplastic tonsils for the presence of EBER I/ 2-positive cells, of which only one harbored enough EBER 112-positive cells (ie, more than 10 EBER 1/2-positive cells per section) for detection of EBV-specific transcripts using RT-PCR analysis. In this hyperplastic tonsil, double-staining revealed the presence of EBER 1R-positive B cells (Fig 1D) . EBER 112-positive T cells were not observed. Most EBER 1R-positive cells expressed no B-or Tcell markers.
Cell Lines
The tightly latent EBV-positive Burkitt's lymphoma cell line RAJ1 and the EBV-transfonned lymphoblastoid cell line KCA were used as positive controls for RT-PCR analysis. The P3HR1-derived HH514C16 cell line served as a negative control for EBNA2 and Y2/HF-spliced BHRFl transcripts. This EBV strain lacks the EBNA2 open reading frame and the last common EBNA-specific exon due to a deletion spanning the BarnHI Y and part of the BamHI H fragment34 (Fig 2) . The EBV-negative cell line BJAB was used as negative control for RT-PCR analysis.
Preparation of Clinical Samples and Cell Lines
For RT-PCR and immunohistochemical analysis, 20 5-hm sections were cut from snap-frozen material. To obtain suitable RNA, 10 sections were homogenized using micropestles (Eppendorf, E.
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Merck Nederland BV, Amsterdam, The Netherlands) in an RNAzol B buffer according to the mamfacture.r's protocol (CinnalBiotec, Houston, TX). Of the EBV-positive cell lines, approximately 5 X lo6 cells were pelleted, and RNA was isolated using the same RNAzol B protocol. RNA was stored in 100% ethanol at -80°C until further processing. The remaining 10 sections were mounted on po1y-Llysine-coated slides, fixed, and used for immunohistochemistry and hematoxylideosin (HE) staining. To confirm that the sections used for RT-PCR contained lymphoma, the first and the last sections of the frozen material used for RT-PCR were HE stained. Cases were excluded if mRNA appeared to be of poor quality, as determined by the presence of 28s and 18s rRNA bands after gel electrophoresis and by RT-PCR using primers specific for glyceraldehyde-3-phosphate dehydrogenase (GAPDH), a well-described housekeeping gene?'
Selection of Oligoprimers and Oligoprobes
RT-PCR analysis was performed using intron flanking primers. The primer sequences and oligoprobes used for analysis of EBNA1, LMP1, BARFO, and H2/HF-spliced BHRFl transcripts have been published p r e v i o~s l y . '~* '~~~~ For analysis of EBNA2, ZEBRA, and Y2/HF-spliced BHRFl transcripts, primers were designated using the PCR plan software (Pcgene release 6.7; IntelliGenetics, Mountain View, CA). All primers and oligoprobes are listed in Table 1 .
Two primer sets were used to investigate the presence of either latent or lytic BHRFl transcripts (Fig 2) . To detect the H2/HFspliced BHRFl transcripts derived from a promoter located on the BamHI H fragment (Hp), activated in lytic infection^:^ a primer combination was used36 amplifying a sequence of 211 bp, specific for spliced mRNA. In amplifying either DNA or unspliced mRNA, a 650-bp fragment is expected. To detect Y2/HF-spliced transcripts derived from the latent C or W promoter, a 248-bp fragment was amplified using a sense primer (Y2) located on the Y2 exon in combination with the BHRF1-specific H3 antisense primer. PCR products of both spliced transcripts were hybridized with an internal oligoprobe located just upstream of the BHRFl antisense primer.
To analyze. EBNA2 transcription, intron flanking primers located on the Y2 exon (identical to the BHRF1-specific sense primer) and on the 5' end of the YH exon, which contains the EBNA2 open reading frame (BYRF~),"~ were used (Fig 2) . Amplified products were hybridized with an oligoprobe located on the Y3 exon, also used as sense primer for amplification of C or W promoter-derived, EBNAl-specific trans~ripts.'~
RT-PCR Analysis
For RT reactions, an amount of RNA equivalent to one 5-pm section (biopsies) and 1 X 10' cells (cell lines) was used. After centrifugation, pellets were resuspended in 5 pL distilled water. RT reactions were performed in a final volume of 20 pL containing 25 pm01 of one to four of each EBV antisense primer specific for the different genes (Table  l) , as described To exclude falsepositive signals caused by DNA amplification, simultaneous reac- OUDEJANS ET AL tions were performed with omission of the RT. For PCR analysis, 5 pL of the cDNA solution and 1 U of ampli Taq DNA polymerase (Perkin Elmer, Emeryville, CA) was added to a buffer containing I .S mmolL MgCI2, 0.2 mmol/L deoxynucleoside triphosphates (dNTPs) and 25 pmol of each of the specific sense and antisense primers (Table l) , in a total volume of 50 pL. After denaturing the DNA for 4 minutes at 94°C 40 rounds of amplification were performed under the following conditions: denaturation at 94°C for 60 seconds, annealing at 55°C for 60 seconds, and extension at 72°C for 90 seconds. Amplified sequences were analyzed by electrophoresis on 1.5% agarose gels, blotted to Genescreen nylon filters (Du Pont, Boston, MA), and hybridized overnight with a specific "P endlabeled internal oligo probes (see Table 1 ). Hybridization was performed at 55°C in a 7% SDS buffer, pH 7.2. Filters were subsequently washed in 2 X SSC, 0.5% SDS at 55°C. Blots were exposed to Kodak X-Omat films (Eastman Kodak, Rochester, NY) for 12 to 72 hours.
The sensitivity of our RT-PCR protocol was estimated by diluting cells of the EBV-transformed lymphoblastoid KCA cell line in EBVnegative BJAB B lymphocytes. We were able to detect Y2/HFand H2IHF-spliced BHRFl transcripts, YS/U/K-and QAJIK-spliced EBNAl transcripts, BARFO and LMP1-specific transcripts from one KCA cell in a background of 1 X lo5 BJAB cells after hybridization and 12 hours of autoradiography. In clinical tissues, EBV-specific transcripts could be detected if a minimum of 10 EBER 1/2-positive cells was present per section. Considering the fact that one 4-pm slide consists of at least 1 X 10' cells, this indicates that in clinical tissues, our RT-PCR method is able to detect EBV-specific transcripts in a minimum of 10 EBV-harboring cells per l X 10' non-EBV harboring cells.
Immunohistochemistry
To detect EBV-specific proteins, antibodies against LMPl (CSI-4, DAKO and S12; Organon Teknika, The net her land^^^), EBNA2 (pE2, DAKO), and ZEBRA (DAKO) were used. Other antibodies used were anti-CD20 (L26, DAKO), anti-CD3 (DAKO), anti-CD45RO (UCHL-l, DAKO), anti-CD30 (BerH2, DAKO), and anti-CD45 (LCA, DAKO). A routine ABC immunoperoxidase technique was used." * The sense primer used for EBNA2 is identical to the BHRFl Y2 sense primer. EBNA2-specific transcripts were detected with the y 3 Primer. also used as sense primer for the detection of EBNAl-specific transcripts.
Combination RISH and Immunohistochemistry
After performing the EBER 1/2 RISH protocol," the remaining peroxidase activity was inactivated with 0.3% H202/methanol and fixed with 4% paraformaldehyde for 10 minutes, followed by the above-described immunohistochemical detection method.
RESULTS

Cell Lines
BHRFI transcription. Both latent Y2MF-spliced and lytic H2MF-spliced BHRFl transcripts were clearly detectable in the EBV-transformed cell line KCA. In the RAJI cell line, strong signals were obtained for C or W promoterderived BHRF1, whereas only a very faint band was observed for HUHF-spliced BHRFl transcripts. As expected, the P3HR1-transformed HH514C16 cell line was positive only for the lytic HUHF-spliced, Hp-derived BHRFl transcript, because it lacks the last common EBNA Y2 exon (Fig 2) . BHRF1-specific transcripts were never observed in the EBV-negative cell line BJAB.
Transcriptional analysis of EBNAI, EBNAZ, BARFO, LMPI, and ZEBRA. BARF0 and LMPl transcripts were easily detected in all EBV-positive cell lines. C or W promoter-as well as F promoter-derived EBNAl transcripts were detected in the KCA cell line. This cell line was also clearly positive for EBNA2 and ZEBRA. In the RAJI cell line, EBNAl was only generated by the C or W promoter, and a strong band was observed for EBNA2, whereas a very faint was detected for ZEBRA. In the HH514C16 cell line, clear ZEBRA-positive signals were detected in the absence of EBNA2. Again, no positive signals were observed in the BJAB cell line.
EBV-Associated B-Cell Lymphomas in lmmunocompromised Patients
BHRFl transcription. BHRFl transcripts were detected in all five B-cell lymphomas: positive signals for both Y2/ W-and H3MF-spliced transcripts in three cases and only Y2EIF-spliced transcripts in the two other cases. In patients without overt immune deficiency, BHRF1-specific transcripts were detected in all four EBV-associated B-cell lymphomas. In two cases, YUHF-spliced transcripts and in two other cases, H;UHF-spliced transcripts were found.
Transcriptional analysis of EBNAl, EBNAZ, BARFO, LMPI, and ZEBRA. In these cases, EBNAl-specific transcripts were generated by both the C and W promoter as well as by the F promoter in all cases except one (case 12253). In this case, only Y3/U/K-spliced transcripts were detected. In all cases, strong signals were observed for EBNA2, BARFO, LMPl, and ZEBRA, which is consistent with previous
EBV-Associated B-Cell Lymphomas in Patients Without Overt Immune Deficiency
BHRFl transcription. In patients without overt immune deficiency, BHRF1-specific transcripts were detected in all tested, EBV-associated B-cell lymphomas. However, in contrast with the immunocompromised patients, either Y2/HFspliced transcripts (cases 1993 and 1959) or HZMF-spliced transcripts (cases 3796 and 12707) were detected.
Transcriptional analysis of EBNAI, EBNA2, BARFO, LMPl, and ZEBRA. EBNAl-specific transcripts were detected in three cases: Y3/U/K-spliced EBNAl in case 1993 and Q/U/K-spliced transcripts in cases 3796 and 12707. In case 1959, no EBNAl transcripts were detected. Although in two cases either the C or W promoter was clearly activated (as shown by the presence of Y2MF-spliced BHRFl and/ or Y3/U/K-spliced EBNAl transcripts), no EBNA2-positive signals were observed. This indicates that downregulation of EBNA2 is not exclusively achieved by differential promoter usage, as has been suggested." ZEBRA-specific transcripts were only detected in the two cases, which were also positive for H2MF-spliced BHRF1, BARFO and LMPl transcripts were easily detected in all cases.
EBV-Associated T-cell Lymphomas
BHRFl transcription.
In EBV-associated T-cell lymphomas, two different EBER 1/2 expression patterns could be observed. In seven cases, all pleiomorphic medium and large-cell lymphomas originating from the nose, EBER 1/2 expression was only detected in neoplastic cells. EBER l/ 2-positive reactive lymphocytes were not observed. In the two other cases ( Table 3 , cases 1660 and 1624), small EBER 1/2-positive, LMP1-negative, morphologically nonneoplastic cells were detected next to large EBER 1/2-positive and LMP1-positive neoplastic cells. In these nine T-cell lymphomas, BHRF1-specific transcripts were only detected in the latter two cases, harboring EBER lM-positive reactive lymphocytes. In case 1660, Y2kIF-spliced BHRFl transcripts were present, and in case 1624, H2EIF-spliced BHRFl transcripts were detected (Fig 3) .
Transcriptional analysis of EBNAI, EBNA2, BARFO, LMPl, and ZEBRA. In three of four tested nasal T-cell lymphomas, Q/U/K-spliced EBNAl-specific transcripts were detected. Y3/U/K-spliced EBNAl transcripts were not found. This is in agreement with previous reports." In one case also harboring EBER U2-positive reactive cells (Table  3 , case 1660), F promoter-derived EBNAl was detected, whereas BHRFl was generated by the C or W promoter. This supports the hypothesis that two separate EBV-harboring populations exist, with F promoter-derived EBNAl in the neoplastic cells and C or W promoter-generated BHRFl transcripts in reactive small lymphocytes. EBNA2 was negative in all cases, whereas BARFO and LMPl were always detected. Moreover, in one case, a faint ZEBRA-positive signal was found (Table 2, case 8070).
EBV-Associated Cases of HD
BHRFl transcription. In five cases, BHRFl transcription could not be detected. In these cases, EBER 1/2 expression was only present in large and intermediate-sized neoplastic cells. In the sixth case (Table 3 , case 909), a weak Y2MF"spliced, BHRF1-positive signal was found. In this case, in contrast to the other cases, a very large number of CD2O-positive small lymphocytes was present with scattered EBER 1/2-positive, LMP1-negative small lymphocytes. Thus, BHRFl transcription in HD could again only be detected in the one case harboring EBER 1/2-positive small lymphocytes (Fig 3) .
For personal use only. on November 11, 2017. by guest www.bloodjournal.org From Tables 2 and 3 . Controls were the KCA cell line with (KCA+) or without (KCA-) reverse transcriptase reaction, the RAJ1 cell line, the HH514C16 cell line, and the EBV-negative BJAB cell line. Amplification of Y2IHF-spliced transcripts generates the 248-bp fragment, and a 211-bp fragment is detected when HP/HF-spIiced transcripts are present. The 650-bp band detected in some cases using the H2lHF PCR primers was due to amplification of DNA, as demonstrated by the 650-bp band present in the KCA-lane. Using the latent primer set, amplification of DNA should yield a 6-kb fragment. Our PCR conditions do not allow amplification of fragments longer than 1 t o 2 kb. Therefore, the 1-t o 1.5-kb fragment detected in the DNA control (KCA-lane) must be considered t o be an artefact.
Transcriptional anal-vsis qf EBNAI, EBNAZ, BARFO, LMPI, and ZEBRA. EBNAI transcription was only analyzed in the BHRFl-positive case of HD (Table 3 , case 909). Both Y3NIK-and QN/K-spliced EBNAI transcripts were found. Others have shown that in cases of HD, EBNAl is usually generated by the F promoter.'* The explanation for the presence of C or W promoter-derived transcripts (Y3/U/ K-spliced EBNAI and Y2/HF-spliced BHRFI) might be that the QN/K-spliced EBNAI transcripts are derived from the neoplastic cells, whereas C or W promoter-derived EBNAI and BHRFI transcripts are derived from the small, EBER I/2-positive lymphocytes. EBNA2 transcripts were never detected, whereas transcription of BARFO and LMPl was always found. In one case (Table 2 , case 1787). a faint ZE-BRA-positive signal was observed.
T-cell Lymphomas With EUER ID Positiviry Mainly Restricted to Nonmalignant Cells
BHRFl transcription.
In these two lymphomas (Table  3 , cases 722 and 1484). EBER 1/2-positive staining was detected in I O to 50 mainly nonmalignant lymphocytes. Both Y2/HF-spliced and H2/HF-spliced BHRFl transcripts were detected, indicating that BHRFl was generated by the C or W promoter as well as by the H promoter.
Transcriptional analysis qf EBNAZ, BARFO, LMPI, and ZEBRA. Although the C or W promoter was activated, as shown by the presence of Y2/HF-spliced transcripts, no EBNA2-specific transcripts were found. ZEBRA-and BARFO-specific transcripts were found in both cases. LMPl transcription could not be detected.
Hyperplastic Tonsil With Sporadic EUER ID-Positive Lymphocytes
BHRFI transcription.
In the hyperplastic tonsil (Table  3 , case 20376), approximately 50 EBER 1/2-positive lymphocytes were found scattered in follicle centers as well as in extrafollicular areas. Again, both Y2/HF-spliced and H2/ HF-spliced BHRFI transcripts were detected, indicating that BHRFl was generated by the C or W promoter as well as by the H promoter (Fig 3) .
Transcriptional analvsis of EBNAI, EUNAZ, BARFO, LMPI, and ZEBRA.
Although BHRFI was generated by both the C or W and H promoter, only Q/U/K-spliced, EBNA I -specific signals were detected. Furthermore, LMPl- Cases also immunohistochemically positive for EBNA2, ZEBRA, and LMP1, respectively.
and BARFO-as well as ZEBRA-positive signals were detected. EBNA2 transcripts were not found.
Immunohistochemical analysis of LMPI, EBNAZ, and ZE-
BRA.
In all B-cell lymphomas except one (case 92-1959), in patients with or without overt immune deficiency, LMPl positivity could be demonstrated using both LMP1-specific antibodies in a restricted number of large blastoid cells ( Fig  1B) . In the T-cell lymphomas, LMPl expression was detected in only three cases (Table 2, case 305 and Table 3 , cases 1660 and 1624). Moreover, although LMPl was detected at the mRNA level, LMPl was not detected at the protein level in the hyperplastic tonsil with sporadic EBER 1/2-positive lymphocytes. Immunohistochemical analysis of EBNA2 confirmed the expression of EBNAZ exclusively in the B-cell lymphomas arising in immunocompromised patients. Although ZEBRA-specific transcripts were detected in patients with or without overt immune deficiency, immunohistochemical detection of ZEBRA was only positive in the five B-cell lymphomas arising in immunocompromised patients. Discrepancies between RT-PCR and immunohistochemistry probably reflect differences in expression levels.
DISCUSSION
The strong functional homology between bcl-2 and BHRF126 and the involvement of bcl-2 in a number of lymphomas prompted us to determine whether transcripts containing the BHRFl open reading frame were present in EBV-associated lymphomas, ie, lymphomas where the large majority of neoplastic cells harbor EBV as shown by the EBER 1/2 RlSH assay.
We detected either Y2MF-spliced or H2MF-spliced B H W l transcripts in all B-cell lymphomas in patients with or without overt immune deficiency. In cases of T-cell lymphomas or HD, BHRF1-specific transcripts were never detected in lymphomas where EBER 1/2 expression was exclusively restricted to the neoplastic cells. However, BHRF1-specific transcripts were detected in two T-cell lymphomas and in one case of HD where EBER 1/2-positive, LMPl -negative, morphologically nonmalignant cells were detected next to EBER 1/2-positive, LMP1-positive neoplastic cells. To be certain in these cases that BHRFl expression is indeed restricted to reactive lymphocytes, morphologic methods such as immunohistochemistry or RISH should be developed. To our knowledge, antibodies against the BHRF1-encoded protein that are sensitive enough for detection of BHRFl on tissue sections are not yet available. Thus far, attempts to detect BHRFl transcripts by in situ hybridization have failed, probably because of the relatively low expression levels of BHRF1. However, the hypothesis that BHRFl transcription in these cases was restricted to the small, sporadic, EBER U2-positive cells is supported by the detection of BHRF1-specific transcripts in one hyperplastic tonsil, where scattered EBER U2-positive lymphocytes were observed, and by detection of BHRFl in two T-cell lymphomas, where EBER 1/2 transcription was mainly restricted to nonmalignant cells. We could not exclude the possibility that in these two Lennert's lymphomas, some of the sporadic EBER 1/2-positive cells were part of the neoplastic population, as not only EBER U2-positive B cells, but also EBER 1/2-positive T cells were found. However, only one or two EBER U2-positive T cells were found per section, which is below the detection level of our RT-PCR assay. Thus, BHRF1-positive signals in these two lymphomas are probably derived from reactive EBER 1/2-positive lymphocytes. Interestingly, in three of five lymphomas from immunocompromised patients, both Y2/HFand H2/HF-spliced BHRFl transcripts were detected. The detection of H2/HFspliced BHRFl transcripts regulated by the H promoter in three cases of B-cell lymphomas in immunocompromised patients was expected, because BHRFl was identified as one of the early EBV genes, and expression of lytic EBV genes in AIDS-related lymphomas has been reported?' However, in seven of nine EBV-associated B-cell lymphomas, Y m Fspliced, BHRF1-specific transcripts were detected. Although we cannot exclude the possibility that these transcripts are generated by a yet unidentified promoter, the inclusion of the Y2 exon, characteristic of the EBNA family,29 strongly suggests that these BHRFl transcripts are generated by the C or W promoter. In most of these cases, activation of the C or W promoter was confirmed by the detection of Y3N/ K-spliced EBNAl transcripts. As activation of the C or W promoter is strongly associated with latency,36 it is likely that YrnF-spliced BHRFl transcripts are generated during latency. This is in agreement with a previous report detecting Y2/HF-spliced BHRFl in a tightly latent lymphoblastoid cell line.29 Moreover, the detection of C or W promoter activation exclusively in the B-cell lymphomas and in cases harboring sporadic EBER 1/2-positive lymphocytes is consistent with in vitro data showing that C or W promoter use depends on a B-cell phenotype?'
In contrast, either Y2/HF-spliced transcripts or H2/HFspliced transcripts were detected in the diffuse EBER 1/2-positive B-cell lymphomas in patients without overt immune deficiency. In the three cases harboring only sporadic EBER U2-positive cells, both Y2/HF-and H2MF-spliced BHRFl transcripts were detected (Table 3, cases 722, 1484, and  20376) . Moreover, in all tested cases positive for H2/HFspliced BHRFl transcripts, ZEBRA-specific transcripts were also found. As ZEBRA is the first protein to be expressed in lytic cells$3 lymphoma cells expressing these proteins have obviously entered the virus lytic cycle.
The observed differential promoter use for BHRFl transcription might implicate an important role for BHRFl in both the latent and lytic cycles of EBV infection. During latency, even low levels of Y2MF-spliced BHRFl transcripts, as observed in could be sufficient to expand cell survival. During the virus lytic cycle, high levels of BHRFl expression could be essential to inhibit apoptosis, allowing the generation of a maximal number of virions.
The selective expression of BHRFl in all EBV-associated
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B-cell lymphomas in patients with or without overt immune deficiency could be significant, as its human homologue, bcl-2, also seems primarily involved in the pathogenesis of FCCL.-
The strong involvement of bcl-2 in the development of FCCL, the presence of BHRFl transcripts in EBVassociated B-cell lymphomas, and the strong functional homology between bcl-2 and BHRFl suggest that both proteins may have identical effects in the pathogenesis of these Bcell lymphomas. The role of bcl-2 in the development of Bcell lymphomas probably involves its ability to prolong cell survival by inhibiting apoptosis,'" and we hypothesize that BHRFl acts in a similar way in EBV-associated B-cell lymphomas. Moreover, the detection of BHRFl in the Bcell lymphomas might be clinically relevant, because it was shown recently that BHRFl protects against cell death induced by DNA-damaging agents used in cancer therapy?8
In conclusion, BHRFl is consistently transcribed in EBVpositive B-cell lymphomas in patients with or without overt immune deficiency. When BHRFl transcription is detected in T-cell lymphomas or in HD, it is probably due to the presence of EBER 1/2-positive, nonmalignant reactive lymphocytes. These data indicate that EBV can be involved in the pathogenesis of lymphomas in different ways. The consistent expression of BHRFl in EBV-associated B-cell lymphomas suggests a pathogenic role for this gene product in these lymphomas in a similar way as the translocated bcl-2 protein. Moreover, in tissues harboring sporadic EBER l / 2-positive lymphocytes, the generation of C or W promoterderived BHRFl transcripts provides a direct mechanism by which EBV could add to immortalization of latently infected lymphocytes.
